Collaborative national medicines management services programme seeks to spread good practice |
|
Full details of the plan for medicines management and the application process are available online. Michael Thompson investigates. Mr Seal can be contacted at the NPC on 0151 794 8137 from April 23 |
|
Pharmacists are already calling the National Prescribing Centre to ask about bidding for a share of the £1.9m to be spent on medicines management pilots in the coming financial year. Mr Richard Seal, who takes up the post of project team leader on April 23 told The Journal: The National Prescribing Centre has already received a number of expressions of interest about the medicines management services programme and I am expecting there to be some strong bids from PCGs and PCTs for the first wave of pilots sites. This is a great opportunity for pharmacists, working as part of a wider multidisciplinary team, to show how they can use their medicines management knowledge and skills to improve the care of patients. Mr Seal said that calls had come from community pharmacists, health authorities, primary care groups and trusts and from GPs. I would strongly urge pharmacists to use their local professional networks to keep abreast of developments and for PCGs and PCTs to start developing their bids now, he added. No clear guidance on how to develop a successful bid is available yet, because the whole scheme is at such an early stage. A meeting to try to clarify this was due to take place on March 21, after The Journal went to press. However, Mr Seal says that a good place to start is with the health authority pharmaceutical adviser. A key factor will be to have a local champion or somebody with expert knowledge. Either he, or Mr Clive Jackson (director of the NPC) would be happy to talk people through the bidding process. Up to 25 pilots There will be up to 25 pilots, each eligible for a maximum of £35,000 to pay for a project facilitator for one year, plus up to £40,000 to release GP practice time. Mr Seal sees the project facilitator as the linchpin to the success of local projects People will need to be good facilitators, able to work across the disciplines and with a good knowledge of primary care. They will need to input a lot of time. It will be difficult for anyone who is providing a front-line service. Although there are clear selection criteria against
which bids will be judged (see panel), it is manifest that there is no
preconceived plan that projects should seek to match. The whole
point of the collaborative approach is to find out what works and what
doesn’t and to spread good practice, Mr Seal says. The 57
varieties approach is very attractive. We are not looking for a set of
rails to travel down and have no firm views on what will succeed, but
there are heavy clues in the national plan. |
Selection criteriaThe criteria against which bids will be judged are summarised below.
|
|
The Department's view In the introduction to the collaborative national medicines management services programme, the Department of Health says that Pharmacy in the future challenges pharmacists to play a full part in delivering the vision of the new National Health Service. It identifies the need to refine and develop the role of pharmacists, as a key professional resource, in helping to optimise medicines use for patients and the NHS. In this context, successful pilot sites will, wherever relevant, be expected to establish close relationships with the separate national pilot trial of a structured medicines management programme, based exclusively in community pharmacies and which is subject to current negotiations between the Department and the Pharmaceutical Services Negotiating Committee. The collaborative approach that the national programme is adopting involves
So far as medicines management is concerned, the overall goal is to help optimise prescribing, plus the experience and outcomes, involving medicines, for each patient, by
Proposals from applicant pilot sites will be expected
to tackle all four goals. They will do this by changing systems that currently
reduce the effectiveness of treatment, restrict access, produce delays
and impair patient well-being. |
|
Michael Thompson is on the staff of The Pharmaceutical Journal |